In this region, North America cancer diagnostics is projected to reach USD 17.72 billion by 2024 from USD 7.59 billion in 2016, at a CAGR of 11.2% in the forecast period 2017 to 2024.
The major factors driving the growth of this market are the technological advancement in the field of early detection of cancer and high investment in cancer research by North America. These factors increase the demand for cancer diagnostic products.

Based on geography, the North America cancer diagnostics market is segmented into 5 geographical regions, such as,
U.S.,
Mexico,
Canada,

North America cancer diagnostics market competition by top players including -
GE Healthcare is going to dominate the cancer diagnostics market, by imaging following with Siemens Healthcare GmbH along with others such as
Hologic Inc.,
Becton, Dickinson & Company.
Thermo Fisher Scientific, Inc. is going to dominate the cancer diagnostics market, by platform based following with Illumina, Inc. along with others such as
Roche Diagnostics,
Abbott Laboratories, Inc.
QIAGEN.

The North America cancer diagnostics market is segmented on the basis of technology, application and geography.
On the basis of technology, North America cancer diagnostics market is segmented into 2 types, namely platform based and instrument based. In 2017, the cancer diagnostics instrument based segment is expected to dominate the market with a share of 69.4%

Cancer diagnostics platform based market is segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), DNA microarrays, flow cytometry and others.
Cancer diagnostics instrument based market is segmented into imaging and biopsy. Imaging is further segmented into magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography- computed tomography (PET-CT), mammography and ultrasound.

On the basis of application, the market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma and others.